SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as market participants debate whether recent price consolidation and integration with financial infrastructure point to a breakout or a prolonged period of manipulation. The community remains deeply polarized, with long-term holders focusing on institutional adoption and potential regulatory clarity, while critics highlight the token's large supply and price correlation with broader market movements.

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

CytomX Therapeutics Inc

CytomX Therapeutics is gaining significant momentum as investors digest updated Phase 1 expansion data for its lead colorectal cancer candidate, Varsetatug Masetecan, alongside a series of analyst price target upgrades. The community is actively debating the stock's potential for a buyout or breakthrough approval, with sentiment split between those capitalizing on the strong price action and skeptics concerned about high short interest and future dilution risks.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is facing intense bearish pressure and sentiment, with investors expressing significant frustration over consistent downward price action despite positive earnings and strategic partnerships like the recent Mastercard stablecoin deal. Many in the community are debating whether to hold through the volatility as a long-term fintech play or to capitulate, while others suggest the stock is being heavily suppressed by short sellers and broader macroeconomic fears surrounding private credit and geopolitical conflict.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore (SOC) is in focus after receiving a federal order under the Defense Production Act to resume hydrocarbon transportation through the Santa Ynez Pipeline System, fueling intense discussion about a potential short squeeze given high short interest. While the community is debating the impact of federal versus state legal friction, many are optimistic about the upcoming target for first oil sales and future production capacity.

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is currently trending due to a surge in market activity and institutional positioning, with investors closely watching the company ahead of its upcoming earnings report. The community is actively debating the credibility of recent acquisition rumors, while closely monitoring the potential impact of new long-acting pipeline data on the company's valuation.

Cingulate, Inc. operates as a clinical stage bio pharmaceutical company using a Precision Timed Release drug delivery platform technology to build a pipeline of next-generation pharmaceutical products. The firm initially focused on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD). It identifies and evaluates additional therapeutic areas, PTR technology employed to develop future product candidates. Cingulate was founded by Shane J. Schaffer, Craig Steven Gilgallon, Raul R. Silva, Matthew N. Brams in May 2012 and is headquartered in Kansas City, KS.

Cingulate Inc

Cingulate Inc. is trending as investors accumulate shares ahead of critical upcoming catalysts, including a highly anticipated U.S. patent approval and a May 31, 2026, PDUFA date for its ADHD treatment, CTx-1301. The community is focused on the stock's low-float structure and recent institutional filings, with many debating the potential for a significant breakout driven by the company's proprietary delivery platform and a massive addressable market.

Better Home & Finance Holding Co. engages in the provision of comprehensive homeownership services. It offers mortgage loans, real estate agent services, and title and homeowner's insurance services. The company was founded in 2014 and is headquartered in New York, NY.

Better Home & Finance Holding Co. - Ordinary Shares - Class A

Better Home & Finance Holding Co.

Better Home & Finance is currently experiencing significant market volatility as investors weigh the potential for a short squeeze against concerns over insider selling and the unwinding of recent momentum. The community is actively debating the company's long-term potential as an AI-driven mortgage platform, with many monitoring its evolving institutional ownership and partnerships despite the stock's recent price retracement.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital is currently trending as investors await a long-anticipated tenant announcement for its data center projects, with community sentiment divided between bullish confidence in the company's energy infrastructure and frustration over repeated delays. Traders are actively debating the impact of recent SEC filings and speculating on the identity of a potential hyperscale tenant, while the stock continues to see high volatility driven by speculative momentum.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is currently experiencing significant market momentum following a major AI infrastructure agreement with Meta, which investors see as a massive validation of its platform's growth trajectory and long-term potential. While the community is actively debating the stock's future valuation and long-term outlook, many are focused on the company's ability to scale high-performance computing capacity as a primary driver for the current bullish sentiment.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing intense community focus as traders speculate on its potential as a core identity layer for AI, fueled by high-profile treasury initiatives and partnerships. Investors are heavily debating the token's long-term utility in "proof-of-personhood" technology while monitoring price volatility driven by institutional interest and broader market sentiment.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Monte Rosa Therapeutics Inc  reported positive Phase 1/2 data for MRT-2359 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). 
In patients with androgen receptor (AR) mutations, the combination achieved a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including two partial RECIST responses and three cases of stable disease, all with reductions in target lesion size. 
Across 15 evaluable patients, the overall RECIST disease control rate was 67%, with 10 of 15 showing tumor shrinkage. The population was heavily pretreated, with 78% previously receiving a second-generation AR inhibitor and 83% prior taxane chemotherapy. 
The regimen was generally well tolerated, with mostly Grade 1–2 adverse events such as fatigue, diarrhea, nausea, and decreased appetite. No patients discontinued treatment due to side effects. 
$GLUE

StockTwits Web

Monte Rosa Therapeutics Inc

Monte Rosa Therapeutics Inc  reported positive Phase 1/2 data for MRT-2359 in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). 
In patients with androgen receptor (AR) mutations, the combination achieved a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate, including two partial RECIST responses and three cases of stable disease, all with reductions in target lesion size. 
Across 15 evaluable patients, the overall RECIST disease control rate was 67%, with 10 of 15 showing tumor shrinkage. The population was heavily pretreated, with 78% previously receiving a second-generation AR inhibitor and 83% prior taxane chemotherapy. 
The regimen was generally well tolerated, with mostly Grade 1–2 adverse events such as fatigue, diarrhea, nausea, and decreased appetite. No patients discontinued treatment due to side effects. 
